POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Clinical trials for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a menin inhibitor tame myelofibrosis when standard drugs fall short?
Disease control Not yet recruitingThis trial investigates whether revumenib, a menin inhibitor, can safely and effectively treat myelofibrosis, a type of bone marrow cancer. The study first tests revumenib alone in patients who have already tried a JAK inhibitor, then tests it in combination with a JAK inhibitor.…
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New drug combo aims to shrink spleen in Hard-to-Treat myelofibrosis
Disease control Not yet recruitingThis phase II trial tests two oral drugs, selinexor and pacritinib, in 26 adults with myelofibrosis who have anemia and low platelets and have not taken JAK inhibitors before. The main goal is to see if the combination can shrink the spleen by at least 35%. The study also tracks …
Matched conditions: POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
Phase: PHASE2 • Sponsor: John Mascarenhas • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC